Pomegra
Function Health closes $450M in non-dilutive growth financing from General Catalyst, just eight months after a $298M Series B, as the company folds in three acquisitions to build an end-to-end preventive diagnostics platform.
- Function's $450M round from General Catalyst's Customer Value Fund is non-dilutive, leaving its $2.5B valuation unchanged.
- Three acquisitions - Ezra (AI body MRI), Getlabs (mobile blood draws), and SuppCo (supplement data) - now underpin the platform.
- The company has raised over $800M total across equity and non-dilutive financing since launching to consumers in 2023.
Lead
Function Health closed $450 million in growth financing from General Catalyst's Customer Value Fund on July 30, 2026, accelerating a build-out strategy that included three acquisitions over roughly 15 months. The round does not reset the company's $2.5 billion valuation, set during an oversubscribed $298 million Series B in November 2025, because the CVF structure returns capital as a capped share of customer revenue rather than taking equity. For Function, that distinction matters: the company gets scale capital without further diluting existing shareholders.
What Is Function Health Actually Selling?
Function's pitch is direct-to-consumer preventive diagnostics at a price that undercuts traditional specialty care. A $365 annual membership covers twice-yearly panels of more than 160 biomarkers - hormones, organ function markers, inflammatory signals, heavy metals, and early cancer indicators. Members can add a full-body MRI through a network of more than 200 partner imaging centers for $899, a price that reaches consumers without a physician referral or insurance preauthorization. The model sits somewhere between concierge medicine and a clinical-grade lab subscription, and it depends on scale to stay at that price point.
Why Did General Catalyst Structure This as Non-Dilutive Financing?
The CVF vehicle is designed precisely for businesses with predictable customer lifetime value - it advances capital to fund sales and marketing, then recovers it as a capped share of the revenue those customers generate. General Catalyst only gets paid when Function gets paid. That alignment is the selling point, but it also means the fund is implicitly underwriting Function's churn assumptions. If member retention softens, the repayment timeline extends; if it accelerates, the fund recycles capital faster. Function's claim - that preventive diagnostics produces higher member stickiness than typical consumer subscriptions - is exactly what this deal structure will stress-test at scale.
What Do the Three Acquisitions Actually Add?
The acquisitions are the more operationally significant part of this story. Ezra, acquired in May 2025, brought an AI-enabled whole-body MRI scanning platform and the infrastructure to deliver sub-$1,000 imaging across Function's existing partner network. Without Ezra, Function was ordering imaging through third parties; after the acquisition, the AI interpretation layer sits inside the product.
Getlabs, acquired in April 2026, added a nationwide mobile phlebotomy network capable of blood collection at members' homes or workplaces. That removes a friction point that likely suppresses completion rates for standard lab-test subscriptions: members who cannot or will not visit a draw site simply skip their panel. Getlabs eliminates that drop-off.
SuppCo, the third acquisition, is smaller in scope. The platform rates the reliability of over-the-counter dietary supplements using a TrustScore system - a natural extension for a company whose members are already tracking 160 biomarkers and asking what they should be taking.
Together, the three deals shift Function from a data aggregator that routes members to third-party services toward a more vertically integrated platform. The question is whether that integration compounds the value of each component or just adds operational complexity.
Strategic Context
The broader preventive health category has attracted significant capital on the premise that catching chronic disease early is cheaper than treating it late. That premise is medically sound; whether it survives as a consumer business model is less settled. Function competes, loosely, with concierge medicine platforms, employer-health programs, and traditional labs that have been building direct-to-consumer channels of their own. The $365 price point is well below concierge alternatives but above what most Americans spend voluntarily on annual health monitoring.
The company launched to consumers in 2023 and, with more than $800 million raised, has never been short of capital to subsidize early growth. The CVF structure suggests General Catalyst believes Function is past the subsidy-dependent phase - or at least that its customer economics can now service non-dilutive debt.
Outlook
Function enters the second half of 2026 with a fully assembled platform: lab testing, at-home blood draws, AI whole-body imaging, and supplement data under one membership. The $450 million gives it runway to push that platform to a materially larger member base without issuing new equity. The company has signaled further acquisitions are possible. Whether the integrated model converts at scale - and whether early-detection data generates the member retention that the CVF structure implicitly assumes - will determine whether this round looks prescient or premature by the time General Catalyst's repayment clock runs out.
